Notably, the BEAT AML dataset revealed that RARα-high samples show much lower ex vivo sensitivity to venetoclax than RARα-low samples [130], which is consistent with the accumulating reports of the association of monocytic AML with resistance to venetoclax [131,132]. Here, RARA is linked to acute myeloid leukemia.